Funding Deters Scientists from Developing New Models

In the 1950s, a young psychiatrist sought an animal with neurons large enough for electrophysiology experiments on learning and memory. The animal, Aplysia californica, eventually got dissected in neurobiology labs around the world. The psychiatrist fared a little better; he was awarded the Nobel Prize.The tale of Eric Kandel and Aplysia, like that of Thomas Hunt Morgan and Drosophila or Sydney Brenner and Caenorhabditis elegans, has become a scientific bedtime story. The moral: Choose the right

Written byKaren Heyman
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

In the 1950s, a young psychiatrist sought an animal with neurons large enough for electrophysiology experiments on learning and memory. The animal, Aplysia californica, eventually got dissected in neurobiology labs around the world. The psychiatrist fared a little better; he was awarded the Nobel Prize.

The tale of Eric Kandel and Aplysia, like that of Thomas Hunt Morgan and Drosophila or Sydney Brenner and Caenorhabditis elegans, has become a scientific bedtime story. The moral: Choose the right animal, work very hard, and you, too, may have a legendary career. But Kandel and others say that few scientists will risk experimenting with an untried organism. Skeptical funding agencies, elusive animals, and a potential dearth of appropriate literature discourage young scientists from branching out.

The failure to explore new models is bad for science, Kandel says. "I think because several model systems have emerged as predominant forms, people are not developing new ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies